INmune Bio’s stock plunged by more than 50% after its TNF inhibitor failed to demonstrate efficacy in Alzheimer’s patients during a Phase II study. The Phase II MINDFuL trial (NCT05318976) was ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), announced the launch of Celselect Slides 2.0 to enhance rare cell and circulating tumor cell (CTC) capture. Compatible with Bio-Rad’s Genesis Cell ...

BioProtocol started its spot trading on Binance, quickly becoming the most valuable DeSci asset. BIO slid in the first hours of trading, but remains promising for the DeSci sector growth in 2025.

Presentation TVT 2023 Case Resolution: Real-World Examples of Surgical Ring and Bioprosthetic Mitral Failure Presenter: Manaf Assafin More slides + ...